Clinical Trial Detail

NCT ID NCT03534804
Title Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Utah
Indications

invasive bladder transitional cell carcinoma

transitional cell carcinoma

Therapies

Cabozantinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.